---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-23-000043"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-12T23:39:12.251536+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q2 net sales $753.8M (-2.3%), adjusted EPS $2.11; raises FY2023 guidance

## Summary
- Reported Q2 diluted EPS of $2.06; adjusted diluted EPS of $2.11, down from $2.47 YoY.
- Net sales declined 2.3% to $753.8M; organic net sales fell 2.5%.
- Proprietary Products segment sales down 5.5% to $618.0M, driven by COVID-19 related decline; base business grew double digits.
- Contract-Manufactured Products segment sales up 15.3% to $135.8M, led by injection-device components.
- FY2023 net sales guidance raised to $2.970-2.995B; adjusted EPS guidance raised to $7.65-7.80.

## SEC filing metadata
- accession: 0000105770-23-000043
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/0000105770-23-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/wst-20230727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-23-000043
- JSON: https://secwatch.observer/filing/0000105770-23-000043.json
- Plain text: https://secwatch.observer/filing/0000105770-23-000043.txt

## Key facts
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported second-quarter 2023 results: revenue $753.8 million, EPS $2.06. Guidance raised.
  - Period: second-quarter 2023
  - Revenue: $753.8 million
  - EPS: $2.06
  - Guidance: raised
  - Result: reported results
  source text: West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2023 and updated full-year 2023 financial guidance. Second-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $753.8 million declined 2.3%; organic net sales declined 2.5%. • Reported-diluted EPS of $2.06, compared to $2.48 in the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/0000105770-23-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.